Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly
Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.
More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.
About Author
More Stories
Esports are booming in Africa – but can its infrastructure keep pace?
AI learns to distinguish between aromas of US and Scottish whiskies
Man who falsely claimed to be bitcoin creator sentenced for continuing to sue developers